ALLG members contribute to the greater collective knowledge through their published research and presentations.
See our members’ published work by year below.
Since we first began in 1973, ALLG trials have contributed to more than 400 publications, presentations and abstracts through our clinical trials program. If you are searching for a publication, presentation or abstract going back to 1982-1999 please contact the ALLG Office.
| Trial | Title | Publication | Authors | Year | Disease Type |
|---|---|---|---|---|---|
| AMLM12 | Idarubicin dose escalation during consolidation therapy for adult acute myeloid Leukaemia. | J Clin Oncol. 35(15):1678-1685. | Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D’Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF, on behalf of the Australasian Leukaemia & Lymphoma Group. | 2017 | Myeloid Leukaemia |
| APML03, APML04 | Determinants of fatal bleeding during induction therapy for acute promyelocytic Leukaemia in the ATRA era. | Blood.129(13):1763-1767. | Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone RM, Powell BL, Geyer S, Laumann K, Rowe JM, Erba HP, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS. | 2017 | Leukaemia |
| BM07 | An Individualised Risk-Adapted Protocol of Pre and Post-Transplant Zoledronic Acid Reduces Bone Loss after AllogeneicStem Cell Transplantation: Results of a Phase II Prospective Trial. | Bone Marrow Transplantation. 2017:1-6. | Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E. | 2017 | Bone Marrow Transplant |
| CML9 | A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukaemia. | J Mol Diagn 19(5):711-21. | Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, and Ross DM. | 2017 | Leukaemia |
| MDS3 | Results of a phase II study of thalidomide and azacitIdine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic Leukaemia (CMML) and low blast count acute myeloid Leukaemia (AML). | Leuk Lymphoma 58:298-307. | Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF: | 2017 | Myeloid Leukaemia |
| MM11 | Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. | Leukaemia 31(8):1727-1734. | Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. | 2017 | Myeloma |
| NHL21 | Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high risk diffuse large B-cell lymphoma and positive interim PET after 4 cycles of R-CHOP-14. | Haematologica 102:356-363. | Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS and Hicks RJ on behalf of the Australasian Leukaemia and Lymphoma Group. | 2017 | Lymphoma |
| NHL25 | Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 35(22):2473-2481. Mo A, McQuilten ZK, Wood EM, Weinkove R. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. | Internal Medicine Journal. 47(6):695-69. | Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas R-O, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouadallah R, Oberic L, Corront B, Choufi B, Deeren D, Gomes da Silva M, Trotman J, Grosicki S, Greil R, Caballero D, and Coiffier B. | 2017 | Lymphoma |
| ALL3 | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic Leukaemia. | Contemporary Clinical Trials Communications 4: 9-13. | Bradstock KF, Morley A, Byth K, Szer J, Prosser I, Cannell P, Irving I, JF Seymour. | 2016 | Leukaemia |
| HD4 | Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score >/= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. | J Clin Oncol. 10;34(17):2028-36. Epub 2016 Apr 25. | Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. | 2016 | Lymphoma |
| HD8 | Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. | N Engl J Med. 374(25):2419-29. | Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. | 2016 | Lymphoma |
| LS14 | The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma. | Clin Exp Immunol. 183(2):206-20. Epub 2015 Nov 13. | Jones K, Wockner L, Brennan RM, Keane C, Chattopadhyay PK, Roederer M, Price DA, Cole DK, Hassan B, Beck K, Gottlieb D, Ritchie DS, Seymour JF, Vari F, Crooks P, Burrows SR, Gandhi MK. | 2016 | Lymphoma |
| MDS3 | Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic Leukaemia (CMML) and low blast count acute myeloid Leukaemia (AML). | Leuk Lymphoma. 58(2):298-307. Epub 2016 Jun 7. | Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF. | 2016 | Lymphoma |
| MM11 | Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. | Leukaemia. epub ahead of print 23 Dec. | Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omede P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. | 2016 | Leukaemia |
| NHL16 | Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. | J Clin Oncol. Epub Aug 22. | Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, Grassi I, Casasnovas RO, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J. | 2016 | Lymphoma |
| NHL21 | Early Treatment Intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM Stem Cell Transplantation in Patients with High Risk Diffuse Large B-cell Lymphoma Patients and Positive Interim PET After 4 Cycles of R-CHOP-14. | Haematologica epub ahead of print 3 Nov. | Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho S-J, Cull G, Fay K, Chong, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson A-M, Warburton P, Wirth A, Seymour JF, Hofman MS, and Hicks RJ on behalf of the Australasian Leukaemia Lymphoma Group (ALLG). | 2016 | Lymphoma |
| NHL16 | Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. | J Clin Oncol 34:2575–82. | Sarkozy C, Trnĕny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Marlton P, Delarue R, Zachee P, Seymour JF, Salles G, Tilly H: | 2016 | Lymphoma |
| NHL16 | Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. | Am J Hematol 91:410–5. | Bachy E, Estell JA, Van de Neste E, Bouaddallah R, Bargay J, Delmer A, Gelas-Dore B, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Lamy T, Dartigues P, Seymour JF, Salles G: | 2016 | Lymphoma |
| APML4 | Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. | The Lancet Haematology 2(9): e357–366. | Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF, Australasian Leukaemia & Lymphoma G. | 2015 | Leukaemia |
| CML9 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. | Blood 125(6): 915–923. | Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP, Australasian Leukaemia & Lymphoma Group (ALLG) | 2015 | Leukaemia |
| LY05 | The addition of Rituximab to Fludarabine and Cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica. | Epub 26 Nov 2015. | Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D. | 2015 | Leukaemia |
| NHL13 | Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. | Haematologica 100(7): 955–963. | Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R, Investigators A-N. | 2015 | Lymphoma |
| NHL21 | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. | The Lancet Haematology 2(10): e445–455. | Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, Seymour JF, Hicks RJ, Gill D, Crooks P, Gould C, Jones K, Griffiths LR, Talaulikar D, Jain S, Tobin J, Gandhi MK. | 2015 | Lymphoma |
| NHL21 | Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. | Blood 125(24): 3679–3687. | Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA. | 2015 | Lymphoma |
| SC04 | Lack of congruence between patients’ and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid Leukaemia: A qualitative study. Epub 13 Feb 2014. | Palliative and Supportive Care 13(2), pp. 255–263. | Wu, S., Chee, D., Ugalde, A., Butow, P., Seymour, J. and Schofield, P. (2014) | 2015 | Myeloid Leukaemia |
| MM11 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. | Lancet Oncology 16: 1617–1629. | Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, Concetta Conticello, Lucio Catalano, Paolo Corradini, Agostina Siniscalchi, Valeria Magarotto, Luděk Pour, Angelo Carella, Alessandra Malfi tano, Daniela Petrò, Andrea Evangelista, Stefano Spada, Norbert Pescosta, Paola Omedè, Philip Campbell, Anna Marina Liberati, Massimo Offi dani, Roberto Ria, Stefano Pulini, Francesca Patriarca, Roman Hajek, Andrew Spencer, Mario Boccadoro, Antonio Palumbo. | 2015 | Myeloma |
| AMLM14 | The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial. | Leukaemia 28(10):1953–9. | Lazenby M, Gilkes AF, Marrin C, Evans A, Hills RK, Burnett AK. | 2014 | Leukaemia |
| AMLM12 | A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. | Brit J Haematol 167: 618–625. | Bradstock KF, Link E, Collins M, Di Iulio J, Lewis ID, Schwarer A, Enno A, Marlton P, Hahn U, Szer J, Cull G and Seymour JF on behalf of the Australasian Leukaemia and Lymphoma Group. | 2014 | Myeloid Leukaemia |
| CLL2 | Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic Leukaemia. | Leuk Lymphoma 55(12):2769–77. | Mulligan SP, Karlsson K, Stromberg M, Jonsson V, Gill D, Hammerstrom J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundstrom G, Johansson H, Brandberg Y, Liliemark J, Juliusson G, Scandinavian, Australasian Leukaemia & Lymphoma Group. | 2014 | Leukaemia |
| CMLALL1 | An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute Leukaemia: long-term results of the CMLALL1 trial. | Leuk Lymphoma 2015; 56(3):630–8 [epub 2014 Aug 4] | Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario J, Rooney K, Lynch K, Bradstock K, Group ftALL. | 2014 | Leukaemia |
| CML6 | Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. | Blood 124(4):511–8. | Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. | 2014 | Myeloid Leukaemia |
| LS14 | Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. | Clin Cancer Res 20(1):253–64. | Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. | 2014 | Lymphoma |
| MM6 | Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. | Lancet Haematology 1(3):e112–e119. | Kalff A, Kennedy N, Smiley A, Prince HM, Roberts AW, Bradstock KF, De Abreu Lourenço R, Frampton C, Spencer AJ. | 2014 | Myeloma |
| NHL7 | A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. | Am J Hematol 89(5):536–41. | Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Browett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M, on behalf of the ALLG. | 2014 | Lymphoma |
| NHL14 | Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. | Lancet Oncol 15(4):424–35. | Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J, Ferhanoglu B, Bradstock K, Linch DC. | 2014 | Lymphoma |
| NHL16 | Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. | Blood 123(17):2740–2. | Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G. | 2014 | Lymphoma |
| NHL16 | Prognostic value of PET-CT after fi rst-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. | The Lancet Haematology 1(1):e17–e27. | Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M. | 2014 | Lymphoma |
| NHL16 | PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. | Eur J Nucl Med Mol Imaging 41(3):408–15. | Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, Vera P, Salles G, Trotman J. | 2014 | Lymphoma |
| NHL16 | Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. | Hematology. 2014. | Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. | 2014 | Lymphoma |
| SC04 | Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid Leukaemia: A qualitative study. | Palliat Support Care. 2014:1–9. | Wu S, Chee D, Ugalde A, Butow P, Seymour J, Schofield P. | 2014 | Myeloid Leukaemia |
| AMLM14 | The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. | Leukaemia (2013);27(1): 75–81 | Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH, Group UKNCRIAW. | 2013 | Myeloid Leukaemia |
| AMLM14 | Clofarabine doubles the response rate in older patients with acute myeloid Leukaemia but does not improve survival. | Blood 122: 1384–1394. | Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D and Hills RK on behalf of the UK National Cancer Research Institute AML Working Group. | 2013 | Myeloid Leukaemia |
| – | Lymphoma Studies by the Australasian Leukaemia and Lymphoma Group. | Transfus Apher Sci 49, no. 2 (2013): 110–2. | Lowenthal, R. M. and Stone, J. M. | 2013 | Miscellaneous |
| AMLM4, AMLM7, AMLM12 | Utility of a Clinical Risk Score to Identify High-Risk Patients with De Novo Acute Myeloid Leukaemia in First Remission after High-Dose Cytarabine (Hidac) Based Induction Chemotherapy. | Br J Haematol 160, no. 6 (2013): 861–3. | Ling, V., Burnett, A. K., Bradstock, K., Seymour, J. F., Hills, R. K. and Wei, A. | 2013 | Myeloid Leukaemia |
| CML8 | Safety and Efficacy of Imatinib Cessation for Cml Patients with Stable Undetectable Minimal Residual Disease: Results from the Twister Study. | Blood 122, no. 4 (2013): 515–22. | Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., Mills, A. K., Melo, J. V., White, D. L., Grigg, A. P. and Hughes, T. P. | 2013 | Myeloid Leukaemia |
| CML6, CML8, CML9 | Distribution of Genomic Breakpoints in Chronic Myeloid Leukaemia: Analysis of 308 Patients. | Leukaemia 27, no. 10 (2013): 2105–7. | Ross, D. M., O'Hely, M., Bartley, P. A., Dang, P., Score, J., Goyne, J. M., Sobrinho-Simoes, M., Cross, N. C., Melo, J. V., Speed, T. P., Hughes, T. P. and Morley, A. A. | 2013 | Myeloid Leukaemia |
| CML8, CML9 | Early Molecular Response and Female Sex Strongly Predict Stable Undetectable Bcr-Abl1, the Criteria for Imatinib Discontinuation in Patients with CML. | Blood 121, no. 19 (2013): 3818–24. | Branford, S., Yeung, D. T., Ross, D. M., Prime, J. A., Field, C. R., Altamura, H. K., Yeoman, A. L., Georgievski, J., Jamison, B. A., Phillis, S., Sullivan, B., Briggs, N. E., Hertzberg, M., Seymour, J. F., Reynolds, J. and Hughes, T. P. | 2013 | Myeloid Leukaemia |
| HDNHL2 | A Randomized Study of Interferon Alpha-2b Versus No Treatment as Consolidation after High Dose Therapy and Autologous Stem Cell Transplantation for Patients with Relapsed Lymphoma. | Oncologist 18, no. 11 (2013): 1189. | Bosly, A., Grigg, A., Holte, H., Gisselbrecht, C., Radford, J., Rossi, A., Lopez-Guillermo, A., Trneny, M., Sebban, C., Hagberg, H., Leal da Costa, F., Colombat, P., Bron, D. and Coiffier, B. | 2013 | Lymphoma |
| LS14 | Serum Cd163 and Tarc as Disease Response Biomarkers in Classical Hodgkin Lymphoma. | Clin Cancer Res 19, no. 3 (2013): 731–42. | Jones, K., Vari, F., Keane, C., Crooks, P., Nourse, J. P., Seymour, L. A., Gottlieb, D., Ritchie, D., Gill, D. and Gandhi, M. K. | 2013 | Lymphoma |
| LY03 | Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients with Untreated Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma. | J Clin Oncol 31, no. 3 (2013): 301–7. | Leblond, V., Johnson, S., Chevret, S., Copplestone, A., Rule, S., Tournilhac, O., Seymour, J. F., Patmore, R. D., Wright, D., Morel, P., Dilhuydy, M. S., Willoughby, S., Dartigeas, C., Malphettes, M., Royer, B., Ewings, M., Pratt, G., Lejeune, J., Nguyen-Khac, F., Choquet, S. and Owen, R. G. | 2013 | Lymphoma |
| SC01 | Galactomannan and PCR Versus Culture and Histology for Directing Use of Antifungal Treatment for Invasive Aspergillosis in High-Risk Haematology Patients: A Randomised Controlled Trial. | Lancet Infect Dis 13, no. 6 (2013): 519–28. | Morrissey, C. O., Chen, S. C., Sorrell, T. C., Milliken, S., Bardy, P. G., Bradstock, K. F., Szer, J., Halliday, C. L., Gilroy, N. M., Moore, J., Schwarer, A. P., Guy, S., Bajel, A., Tramontana, A. R., Spelman, T., Slavin, M. A.; Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group. | 2013 | Stem Cell Transplant |
| CML6, CML9 | (BCR-ABL1 doubling-times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold-rise: implications for monitoring and management. | Blood 119(18): 4264–4271. | Branford, S., Yeung, D. T., Prime, J. A., Choi, S. Y., Bang, J. H., Park, J. E., Kim, D. W., Ross, D. M. and Hughes, T. P. | 2012 | Leukaemia |
| PT1 | Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. | Blood 120(7): 1409–1411. | Campbell, P. J., Maclean, C., Beer, P. A., Buck, G., Wheatley, K., Kiladjian, J. J., Forsyth, C., Harrison, C. N. and Green, A. R. | 2012 | Leukaemia |
| NHL16 | Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. | Blood 120(13): 2650–2657. | Ghesquieres, H., Cartron, G., Seymour, J. F., Delfau-Larue, M. H., Offner, F., Soubeyran, P., Perrot, A., Brice, P., Bouabdallah, R., Sonet, A., Dupuis, J., Casasnovas, O., Catalano, J. V., Delmer, A., Jardin, F., Verney, A., Dartigues, P. and Salles, G. | 2012 | Lymphoma |
| NHL13 | Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma. | J Clin Oncol 30 (in print). | Gisselbrecht, C., Schmitz, N., Mounier, N., Gill, D. S., Linch, D. C., Trneny, M., Bosly, A., Milpied, N. J., Radford, J., Ketterer, N., Shpilberg, O., Duhrsen, U., Hagberg, H., Ma, D. D., Viardot, A., Lowenthal, R., Briere, J., Salles, G., Moskowitz, C. H. and Glass, B. | 2012 | Lymphoma |
| LS13 | WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid Leukaemia when measured post-consolidation. | Leuk Res 36(4): 453–458. | Gray, J. X., McMillen, L., Mollee, P., Paul, S., Lane, S., Bird, R., Gill, D., Saal, R. and Marlton, P. | 2012 | Leukaemia |
| MM6 | Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. | Leuk Lymphoma 53(9): 1728–1734. | Ho, P. J., Brown, R. D., Spencer, A., Jeffels, M., Daniher, D., Gibson, J. and Joshua, D. E. | 2012 | Myeloma |
| APML3 | Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic Leukaemia. | Haematologica 97(2): 227–234. | Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., Browett, P., Brighton, T., Chong, L., Springall, F., Ayling, J., Catalano, A., Supple, S., Collins, M., Di Iulio, J. and Reynolds, J. | 2012 | Leukaemia |
| APML4 | All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic Leukaemia (APML4). | Blood 120(8): 1570–1580. | Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., Reynolds, J., Di Iulio, J., Tiley, C., Taylor, K., Filshie, R., Seldon, M., Taper, J., Szer, J., Moore, J., Bashford, J. and Seymour, J. F. | 2012 | Leukaemia |
| LS14 | Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. | Am J Hematol 87(3): 258–265. | Jones, K., Nourse, J. P., Keane, C., Crooks, P., Gottlieb, D., Ritchie, D. S., Gill, D. and Gandhi, M. K. | 2012 | Lymphoma |
| MM8 | A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. | Br J Haematol 157(6): 766–769. | Mollee, P., Tiley, C., Cunningham, I., Moore, J., Prince, H. M., Cannell, P., Gibbons, S., Tate, J., Paul, S., Fan, H. M. and Gill, D. S. | 2012 | Myeloid Leukaemia |
| NHL10 | CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. A | nn Oncol 23(5): 1267–1273. | Schmitz, N., Zeynalova, S., Glass, B., Kaiser, U., Cavallin-Stahl, E., Wolf, M., Haenel, M., Loeffler, M., Truemper, L. and Pfreundschuh, M. | 2012 | Lymphoma |
| AMLM7,AMLM9 | Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. | Leukaemia 26(2): 362–365. | van der Jagt, A., Muirhead, J., Seymour, J. F., Bradstock, K. F., Paul, E. and Wei, A. | 2012 | Myeloid Leukaemia |
| CML6 | Classification of patients with chronic myeloid Leukaemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. | J Clin Oncol 30(10): 1144–1145. | White, D. L. and Hughes, T. P. | 2012 | Myeloid Leukaemia |
| LY02 | Limited Chemotherapy and Shrinking Field Radiotherapy for Osteolymphoma (Primary Bone Lymphoma): Results From the Trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 Prospective Trial. | Int J Radiat Oncol Biol Phys 80(4): 1164–1170. | Christie, D., Dear, K., Le, T., Barton, M., Wirth, A., Porter, D., Roos, D. and Pratt, G. | 2011 | Lymphoma |
| SC01 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. | Leuk Lymphoma 52(2): 179–193. | Morrissey, C. O., Chen, S. C., Sorrell, T. C., Bradstock, K. F., Szer, J., Halliday, C. L., Gilroy, N. M., Schwarer, A. P. and Slavin, M. A. | 2011 | Stem Cell Transplant |
| NHL10 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. | Lancet Oncol 12(11): 1013–1022. | Pfreundschuh, M., Kuhnt, E., Trumper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P. L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., Lopez-Guillermo, A., Poeschel, V., Grass, S., Loeffler, M. and Murawski, N. | 2011 | Lymphoma |
| NHL10 | Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. | Ann Oncol 22(3): 664–670. | Rieger, M., Osterborg, A., Pettengell, R., White, D., Gill, D., Walewski, J., Kuhnt, E., Loeffler, M., Pfreundschuh, M. and Ho, A. D. | 2011 | Lymphoma |
| NHL16 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. | Lancet 377(9759): 42–51. | Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., Caballero, D., Haioun, C., Pedersen, L. M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M. G., Sebban, C., Lister, A., Estell, J. A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. and Tilly, H. | 2011 | Lymphoma |
| LY02 | Limited Chemotherapy and Shrinking Field Radiotherapy for Osteolymphoma (Primary Bone Lymphoma): Results From the Trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 Prospective Trial. | Int J Radiat Oncol Biol Phys 80(4): 1164–1170. | Christie, D., Dear, K., Le, T., Barton, M., Wirth, A., Porter, D., Roos, D. and Pratt, G. | 2011 | Lymphoma |
| SC01 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. | Leuk Lymphoma 52(2): 179–193. | Morrissey, C. O., Chen, S. C., Sorrell, T. C., Bradstock, K. F., Szer, J., Halliday, C. L., Gilroy, N. M., Schwarer, A. P. and Slavin, M. A. | 2011 | Stem Cell Transplant |
| NHL10 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. | Lancet Oncol 12(11): 1013–1022. | Pfreundschuh, M., Kuhnt, E., Trumper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P. L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., Lopez-Guillermo, A., Poeschel, V., Grass, S., Loeffler, M. and Murawski, N. | 2011 | Lymphoma |
| NHL10 | Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. | Ann Oncol 22(3): 664–670. | Rieger, M., Osterborg, A., Pettengell, R., White, D., Gill, D., Walewski, J., Kuhnt, E., Loeffler, M., Pfreundschuh, M. and Ho, A. D. | 2011 | Lymphoma |
| NHL16 | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. | Lancet 377(9759): 42–51. | Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., Caballero, D., Haioun, C., Pedersen, L. M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M. G., Sebban, C., Lister, A., Estell, J. A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. and Tilly, H. | 2011 | Lymphoma |
| NHL16 | Rituximab maintenance therapy for follicular lymphoma — Authors' reply. | Lancet 377(9772): 1151–1152. | Salles, G., Seymour , J. F., Offner, F., Lopez-Guillermo, A., Mege, L. and Tilly, H. | 2011 | Lymphoma |
| NHL16 | Positron Emission Tomography-Computed Tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. | J Clin Oncol 29(23): 3194–3200. | Trotman, J., Fournier, M., Lamy, T., Seymour, J. F., Sonet, A., Janikova, A., Shpilberg, O., Gyan, E., Tilly, H., Estell, J., Forsyth, C., Decaudin, D., Fabiani, B., Gabarre, J., Salles, B., Van Den Neste, E., Canioni, D., Garin, E., Fulham, M., Vander Borght, T. and Salles, G. | 2011 | Lymphoma |
| HD3 | Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. | Leuk Lymphoma 52(5): 786–795. | Wirth, A., Grigg, A., Wolf, M., Goldstein, D., Johnson, C., Davis, S., Dutu, G., Kypreos, P., Smith, C., Kneebone, A., Herzberg, M., Joseph, D., Catalano, J., Roos, D., Stone, J. and Reynolds, J. | 2011 | Lymphoma |
| NHL13 | The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. | J Clin Oncol 29: 4079-4087. | C Thieblemont, J Briere, N Mounier, H-U Voelker, W Cuccuini, E Hirchaud, A Rosenwald, A Jack, C Sundstrom, S Cogliatti, P Trougouboff, L Boudova, L Ysebaert, J Soulier, C Chevalier, D Bron, N Schmitz, P Gaulard, R Houlgatte, and C Gisselbrecht. | 2011 | Lymphoma |
| NHL13 | Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. | J Clin Oncol 28(27): 4184–4190. | Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Briere, J., Moskowitz, C. H. and Schmitz, N. | 2010 | Lymphoma |
| NHLLOW1 | Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. | Leuk Lymphoma 51(4): 641–649. | Grigg, A. P., Stone, J., Milner, A. D., Schwarer, A. P., Wolf, M., Prince, H. M., Seymour, J., Gill, D., Ellis, D. and Bashford, J. | 2010 | Lymphoma |
| NHL8 | Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. | Br J Haematol 149(2): 237–243. | Linch, D. C., Yung, L., Smith, P., Maclennan, K., Jack, A., Hancock, B., Cunningham, D., Hoskin, P., Qian, W., Holte, H., Boesen, A. M., Grigg, A., Browett, P. and Trneny, M. | 2010 | Lymphoma |
| – | Enrolment of patients to clinical trials in haematological cancer in New South Wales: current status, perceived barriers and opportunities for improvement. | Intern Med J 40(2): 133–138. | Murray, P., Kerridge, I., Tiley, C., Catanzariti, A., Welberry, H., Lean, C., Sinclair, S., Bishop, J. and Bradstock, K. | 2010 | Miscellaneous |
| CML8 | Patients with chronic myeloid Leukaemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent Leukaemia by DNA PCR. | Leukaemia 24(10): 1719–1724. | Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Bartley, P. A., Slader, C., Field, C., Dang, P., Filshie, R. J., Mills, A. K., Grigg, A. P., Melo, J. V. and Hughes, T. P. | 2010 | Myeloid Leukaemia |
| NHLLOW4 | Reply to U. Duhrsen et al. | J Clin Oncol 28(30): e614. | van Oers, M. H., Tonnissen, E., Van Glabbeke, M., Giurgea, L., Jansen, J. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Vranovsky, A., Holte, H., Hagenbeek, A. and van der Reijden, B. A. | 2010 | Lymphoma |
| NHLLOW4 | BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. | J Clin Oncol 28(13): 2246–2252. | van Oers, M. H., Tonnissen, E., Van Glabbeke, M., Giurgea, L., Jansen, J. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Vranovsky, A., Holte, H., Hagenbeek, A. and van der Reijden, B. A. | 2010 | Lymphoma |
| NHLLOW4 | Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. | J Clin Oncol 28(17): 2853–2858. | van Oers, M. H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H. and Hagenbeek, A. | 2010 | Lymphoma |
| MM6 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. | Leuk Lymphoma 50(11): 1860–1864. | Brown, R. D., Spencer, A., Ho, P. J., Kennedy, N., Kabani, K., Yang, S., Sze, D. M., Aklilu, E., Gibson, J. and Joshua, D. E. | 2009 | Myeloma |
| LY02 | Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). | J Med Imaging Radiat Oncol 53(2): 203–206. | Christie, D., Le, T., Watling, K., Cornes, D., O'Brien, P. and Hitchins, R. | 2009 | Lymphoma |
| LY05 | Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. | Leuk Lymphoma 50(2): 211–215. | Eve, H. E., Linch, D., Qian, W., Ross, M., Seymour, J. F., Smith, P., Stevens, L. and Rule, S. A. | 2009 | Lymphoma |
| LY05 | Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab. | Leuk Lymphoma 50(3): 463–465. | Eve, H. E., Seymour, J. F. and Rule, S. A. | 2009 | Lymphoma |
| MM6 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. | J Clin Oncol 27(11): 1788–1793. | Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J. and Kennedy, N. | 2009 | Myeloma |
| MM6 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. | Leuk Lymphoma 50(11): 1860–1864. | Brown, R. D., Spencer, A., Ho, P. J., Kennedy, N., Kabani, K., Yang, S., Sze, D. M., Aklilu, E., Gibson, J. and Joshua, D. E. | 2009 | Myeloma |
| LY02 | Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). | J Med Imaging Radiat Oncol 53(2): 203–206. | Christie, D., Le, T., Watling, K., Cornes, D., O'Brien, P. and Hitchins, R. | 2009 | Lymphoma |
| LY05 | Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. | Leuk Lymphoma 50(2): 211–215. | Eve, H. E., Linch, D., Qian, W., Ross, M., Seymour, J. F., Smith, P., Stevens, L. and Rule, S. A. | 2009 | Lymphoma |
| LY05 | Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab. | Leuk Lymphoma 50(3): 463–465. | Eve, H. E., Seymour, J. F. and Rule, S. A. | 2009 | Lymphoma |
| MM6 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. | J Clin Oncol 27(11): 1788–1793. | Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J. and Kennedy, N. | 2009 | Myeloma |
| MM6 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. | Leuk Lymphoma 50(11): 1860–1864. | Brown, R. D., Spencer, A., Ho, P. J., Kennedy, N., Kabani, K., Yang, S., Sze, D. M., Aklilu, E., Gibson, J. and Joshua, D. E. | 2009 | Myeloma |
| LY02 | Quality assurance audit: a prospective non-randomised trial of chemotherapy and radiotherapy for osteolymphoma (TROG 99.04/ALLG LY02). | J Med Imaging Radiat Oncol 53(2): 203–206. | Christie, D., Le, T., Watling, K., Cornes, D., O'Brien, P. and Hitchins, R. | 2009 | Lymphoma |
| LY05 | Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. | Leuk Lymphoma 50(2): 211–215. | Eve, H. E., Linch, D., Qian, W., Ross, M., Seymour, J. F., Smith, P., Stevens, L. and Rule, S. A. | 2009 | Lymphoma |
| LY05 | Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab. | Leuk Lymphoma 50(3): 463–465. | Eve, H. E., Seymour, J. F. and Rule, S. A. | 2009 | Lymphoma |
| MM6 | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. | J Clin Oncol 27(11): 1788–1793. | Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J. and Kennedy, N. | 2009 | Myeloma |
| SC01 | Preventing invasive fungal infection during hospital building works. | Intern Med J 38(6b): 538–541. | Chang, C. C., Athan, E., Morrissey, C. O. and Slavin, M. A. | 2008 | Stem Cell Transplant |
| CML6 | Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. | Blood 112(10): 3965–3973. | Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M. F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A. K., Fay, K., Durrant, S., Januszewicz, H., Joske, D., Underhill, C., Dunkley, S., Lynch, K. and Grigg, A. | 2008 | Myeloid Leukaemia |
| AMLM13 | A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid Leukaemia and predicts subsequent morphologic relapse. | Leuk Lymphoma 49(3): 517–523. | Lane, S., Saal, R., Mollee, P., Jones, M., Grigg, A., Taylor, K., Seymour, J., Kennedy, G., Williams, B., Grimmett, K., Griffiths, V., Gill, D., Hourigan, M. and Marlton, P. | 2008 | Myeloid Leukaemia |
| LY06 | A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). | Blood 112(6): 2248–2260. | Mead, G. M., Barrans, S. L., Qian, W., Walewski, J., Radford, J. A., Wolf, M., Clawson, S. M., Stenning, S. P., Yule, C. L. and Jack, A. S. | 2008 | Lymphoma |
| SC01 | Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. | Intern Med J 38(6b): 477–495. | Morrissey, C. O., Bardy, P. G., Slavin, M. A., Ananda-Rajah, M. R., Chen, S. C., Kirsa, S. W., Ritchie, D. S. and Upton, A. | 2008 | Lymphoma |
| NHL10 | Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. | Lancet Oncol 9(5): 435–444. | Pfreundschuh, M., Ho, A. D., Cavallin-Stahl, E., Wolf, M., Pettengell, R., Vasova, I., Belch, A., Walewski, J., Zinzani, P. L., Mingrone, W., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Corrado, C., Scheliga, A., Loeffler, M. and Kuhnt, E. | 2008 | Lymphoma |
| CML8 | Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid Leukaemia: implications for defining sensitivity in minimal residual disease. | Clin Chem 54(9): 1568–1571. | Ross, D. M., Watkins, D. B., Hughes, T. P. and Branford, S. | 2008 | Myeloid Leukaemia |
| – | Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2008. | Intern Med J 38(6b): 457–467. | Slavin, M. A. | 2008 | Miscellaneous |
| SC01 | Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. | Intern Med J 38(6b): 468–476. | Slavin, M. A., Heath, C. H., Thursky, K. A., Morrissey, C. O., Szer, J., Ling, L. M., Milliken, S. T. and Grigg, A. P. | 2008 | Stem Cell Transplant |
| MM6 | Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. | BMC Clin Pharmacol 8: 2. | Spencer, A., Roberts, A., Kennedy, N., Ravera, C., Cremers, S., Bilic, S., Neeman, T., Copeman, M., Schran, H. and Lynch, K. | 2008 | Myeloma |
| SC01 | Recommendations for the treatment of established fungal infections. | Intern Med J 38(6b): 496–520. | Thursky, K. A., Playford, E. G., Seymour, J. F., Sorrell, T. C., Ellis, D. H., Guy, S. D., Gilroy, N., Chu, J. and Shaw, D. R. | 2008 | Miscellaneous |
| PT1 | Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. | Blood 111(1): 60–70. | Wilkins, B. S., Erber, W. N., Bareford, D., Buck, G., Wheatley, K., East, C. L., Paul, B., Harrison, C. N., Green, A. R. and Campbell, P. J. | 2008 | Bone Marrow Transplant |
| SC01 | Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. | Intern Med J 38(6b): 521–537. | Worth, L. J., Blyth, C. C., Booth, D. L., Kong, D. C., Marriott, D., Cassumbhoy, M., Ray, J., Slavin, M. A. and Wilkes, J. R. | 2008 | Miscellaneous |
| CML5 | Efficacy and safety of imatinib in patients with chronic myeloid Leukaemia and complete or near-complete cytogenetic response to interferon-alpha. | Cancer 110(4): 801–808. | Branford, S., Hughes, T., Milner, A., Koelmeyer, R., Schwarer, A., Arthur, C., Filshie, R., Moreton, S., Lynch, K. and Taylor, K. | 2007 | Myeloid Leukaemia |
| APML4 | The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic Leukaemia. | Blood 110(12): 4073–4076. | Catalano, A., Dawson, M. A., Somana, K., Opat, S., Schwarer, A., Campbell, L. J. and Iland, H. | 2007 | Leukaemia |
| LY02 | Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? | Intern Med J 37(10): 680–686. | Christie, D. R., Gabriel, G. S. and Dear, K. | 2007 | Lymphoma |
| LS07 | Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. | Blood 110(4): 1326–1329. | Gandhi, M. K., Moll, G., Smith, C., Dua, U., Lambley, E., Ramuz, O., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. | 2007 | Lymphoma |
| AMLM11 | A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid Leukaemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. | Biol Blood Marrow Transplant 13(5): 560–567. | Grigg, A. P., Gibson, J., Bardy, P. G., Reynolds, J., Shuttleworth, P., Koelmeyer, R. L., Szer, J., Roberts, A. W., To, L. B., Kennedy, G. and Bradstock, K. F. | 2007 | Myeloid Leukaemia |
| AMLM10 | Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study. | Drugs Aging 24(6): 481–488. | Manoharan, A., Reynolds, J., Matthews, J., Baxter, H., Di Iulio, J., Leahy, M. and Juneja, S. | 2007 | Myeloid Leukaemia |
| ALL2 | Outcome of treatment after first relapse in adults with acute lymphoblastic Leukaemia initially treated by the LALA-94 trial. | Leukaemia 21(9): 1907–1914. | Tavernier, E., Boiron, J. M., Huguet, F., Bradstock, K., Vey, N., Kovacsovics, T., Delannoy, A., Fegueux, N., Fenaux, P., Stamatoullas, A., Tournilhac, O., Buzyn, A., Reman, O., Charrin, C., Boucheix, C., Gabert, J., Lheritier, V., Vernant, J. P., Dombret, H. and Thomas, X. | 2007 | Leukaemia |
| ALL2 | Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic Leukaemia and treated according to the LALA-87 and LALA-94 trials. | Cancer 110(12): 2747–2755. | Tavernier, E., Le, Q. H., de Botton, S., Dhedin, N., Bulabois, C. E., Reman, O., Vey, N., Lheritier, V., Dombret, H. and Thomas, X. | 2007 | Leukaemia |
| CML6 | Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid Leukaemia. | J Clin Oncol 25(28): 4445–4451. | White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M. F., Lynch, K., To, L. B. and Hughes, T. | 2007 | Myeloid Leukaemia |
| CML6 | Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. | Blood 110(12): 4064–4072. | White, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P. W. and Hughes, T. | 2007 | Myeloid Leukaemia |
| NHL_X3 | (The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. | Eur J Haematol 76(6): 473–480. | Campbell, J., Seymour, J. F., Matthews, J., Wolf, M., Stone, J. and Juneja, S. | 2006 | Lymphoma |
| ALL2 | Autologous stem cell transplantation in adults with acute lymphoblastic Leukaemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. | Leukaemia 20(2): 336–344. | Dhedin, N., Dombret, H., Thomas, X., Lheritier, V., Boiron, J. M., Rigal-Huguet, F., Vey, N., Kuentz, M., Reman, O., Witz, F., Delannoy, A., Kovacsovics, T., Bradstock, K., Charrin, C., Boucheix, C., Gabert, J., Blaise, D., Fiere, D. and Vernant, J. P. | 2006 | Leukaemia |
| LS09 | Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. | Clin Cancer Res 12(2): 460–464. | Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. | 2006 | Lymphoma |
| BM02 | Pamidronate reduces bone loss after allogeneic stem cell transplantation. | J Clin Endocrinol Metab 91(10): 3835–3843. | Grigg, A. P., Shuttleworth, P., Reynolds, J., Schwarer, A. P., Szer, J., Bradstock, K., Hui, C., Herrmann, R. and Ebeling, P. R. | 2006 | Stem Cell Transplant |
| SC01 | Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy. | Medical Mycology 44(suppl.): S333–348. | Morrissey, C. O. and Slavin, M. A. | 2006 | Stem Cell Transplant |
| NHL10 | CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. | Lancet Oncol 7(5): 379–391. | Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P. L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. and Loeffler, M. | 2006 | Lymphoma |
| CML6 | Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. | Leukaemia 20(4): 664–670. | Ross, D. M., Branford, S., Moore, S. and Hughes, T. P. | 2006 | Myeloid Leukaemia |
| HD5 | Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J | Immunol 177(7): 4897–4906. | Smith, C., Cooper, L., Burgess, M., Rist, M., Webb, N., Lambley, E., Tellam, J., Marlton, P., Seymour, J. F., Gandhi, M. and Khanna, R. | 2006 | Lymphoma |
| NHLLOW4 | Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. | Blood 108(10): 3295–3301. | van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., Van't Veer, M., Vranovsky, A., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C. and Hagenbeek, A. | 2006 | Lymphoma |
| LY04 | Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). | Int J Radiat Oncol Biol Phys 64: 408–13 (2006). | O’Brien PC, Roos DE, Pratt G, Liew KH, Barton MB, Poulsen MG, Olver IN, Trotter GE, for the Trans-Tasman Radiation Oncology Group. | 2006 | Lymphoma |
| HDNHL3 | A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. | Leuk Lymphoma 46(2): 197–206. | Biagi, J. J., Herbert, K. E., Smith, C., Abdi, E., Leahy, M., Falkson, C., Wolf, M., Januszewicz, H., Seymour, J. F., Richards, K., Matthews, J. P., Dale, B. and Prince, H. M. | 2005 | Lymphoma |
| AMLM7 | A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid Leukaemia in first remission after induction therapy containing high-dose cytarabine. | Blood 105(2): 481–488. | Bradstock, K. F., Matthews, J. P., Lowenthal, R. M., Baxter, H., Catalano, J., Brighton, T., Gill, D., Eliadis, P., Joshua, D., Cannell, P., Schwarer, A. P., Durrant, S., Gillett, A., Koutts, J., Taylor, K., Bashford, J., Arthur, C., Enno, A., Dunlop, L., Szer, J., Leahy, M., Juneja, S. and Young, G. A. | 2005 | Myeloid Leukaemia |
| PT1 | Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. | Lancet 366(9501): 1945–1953. | Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., Vassiliou, G. S., Milligan, D. W., Smith, S. R., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Harrison, C. N. and Green, A. R. | 2005 | Miscellaneous |
| AMLM8 | Prognostic features for response and survival in elderly patients with de novo acute myeloid Leukaemia treated with mitoxantrone and intermediate dose cytarabine. | Leuk Lymphoma 46(3): 367–375. | Grigg, A. P., Reynolds, J., McQuillan, A., Juneja, S. K., Di Iulio, J., Hui, C., Smith, C., Kimber, R. and Bradstock, K. F. | 2005 | Myeloid Leukaemia |
| PT1 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. | N Engl J Med 353(1): 33–45. | Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., Revell, P., Woodcock, B. E. and Green, A. R. | 2005 | Miscellaneous |
| LY03 | Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. | Clin Lymphoma 5(4): 294–297. | Johnson, S. A., Owen, R. G., Oscier, D. G., Leblond, V., Levy, V., Jaeger, U. and Seymour, J. F. | 2005 | Lymphoma |
| MM5 | Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. | Bone Marrow Transplant 35(10): 971–977. | Spencer, A., Horvath, N., Gibson, J., Prince, H. M., Herrmann, R., Bashford, J., Joske, D., Grigg, A., McKendrick, J., Prosser, I., Lowenthal, R., Deveridge, S. and Taylor, K. | 2005 | Myeloma |
| CML6 | In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. | Blood 106(7): 2520–2526. | White, D., Saunders, V., Lyons, A. B., Branford, S., Grigg, A., To, L. B. and Hughes, T. | 2005 | Myeloid Leukaemia |
| HDNHL1 | Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study. | Bone Marrow Transplant 35(3): 291–298. | Wirth, A., Prince, H. M., Wolf, M., Stone, J. M., Matthews, J., Gibson, J., Macleod, C., Szer, J., Grigg, A., To, B., Roos, D., Schwarer, A. P. and Davis, S. | 2005 | Lymphoma |
| NHL_X3 | Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma. | Ann Oncol 14(2): 273–276. | Campbell, J. K., Matthews, J. P., Seymour, J. F., Wolf, M. M. and Juneja, S. K. | 2003 | Lymphoma |
| HD2 | High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. | J Clin Oncol 21(12): 2320–2325. | Federico, M., Bellei, M., Brice, P., Brugiatelli, M., Nagler, A., Gisselbrecht, C., Moretti, L., Colombat, P., Luminari, S., Fabbiano, F., Di Renzo, N., Goldstone, A. and Carella, A. M. | 2003 | Lymphoma |
| APML3 | Diagnosis and molecular monitoring of acute promyelocytic Leukaemia using DzyNA reverse transcription-PCR to quantify PML/RARalpha fusion transcripts. | Clin Chem 48(8): 1338–1343. | Applegate, T. L., Iland, H. J., Mokany, E. and Todd, A. V. | 2002 | Leukaemia |
| APML3 | Molecular Monitoring of Acute Promyelocytic Leukaemia by DzyNA Reverse Transcription-PCR | Clin Chem 48(10): 1858–1860. | Applegate, T. L., Iland, H. J., Mokany, E. and Todd, A. V. | 2002 | Leukaemia |
| ALL2 | Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic Leukaemia--results of the prospective multicenter LALA-94 trial. | Blood 100(7): 2357–2366. | Dombret, H., Gabert, J., Boiron, J. M., Rigal-Huguet, F., Blaise, D., Thomas, X., Delannoy, A., Buzyn, A., Bilhou-Nabera, C., Cayuela, J. M., Fenaux, P., Bourhis, J. H., Fegueux, N., Charrin, C., Boucheix, C., Lheritier, V., Esperou, H., MacIntyre, E., Vernant, J. P. and Fiere, D. | 2002 | Leukaemia |
| LY01 | An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. | Ann Oncol 13(8): 1264–1274. | Mead, G. M., Sydes, M. R., Walewski, J., Grigg, A., Hatton, C. S., Pescosta, N., Guarnaccia, C., Lewis, M. S., McKendrick, J., Stenning, S. P. and Wright, D. | 2002 | Lymphoma |
| AMLM7 | (Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. | Leukaemia 15(9): 1331–1338. | Bradstock, K., Matthews, J., Young, G., Lowenthal, R., Baxter, H., Arthur, C., Bashford, J., Brighton, T., Cannell, P., Dunlop, L., Durrant, S., Enno, A., Eliadis, P., Gill, D., Gillett, A., Gottlieb, D., Januszewicz, H., Joshua, D., Leahy, M., Schwarer, A. and Taylor, K. | 2001 | Myeloid Leukaemia |
| AMLM2, AMLM4 | Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. | Br J Haematol 113(3): 727–736. | Matthews, J. P., Bishop, J. F., Young, G. A., Juneja, S. K., Lowenthal, R. M., Garson, O. M., Cobcroft, R. G., Dodds, A. J., Enno, A., Gillett, E. A., Herrmann, R. P., Joshua, D. E., Ma, D. D., Szer, J., Taylor, K. M., Wolf, M. and Bradstock, K. F. | 2001 | Myeloid Leukaemia |
| NHLLOW5 | Management of localised low-grade follicular lymphomas. | Austral Radiol. | McManus, M. P. and Seymour, J. F. | 2001 | Lymphoma |
| MM_X2 | Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. | Br J Haematol 113(4): 1020–1034. | The Myeloma Trialists' Collaborative Group | 2001 | Myeloma |
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
wpDataTable with provided ID not found!
TRIAL: ALL3
Bradstock KF, Morley A, Byth K, Szer J, Prosser I, Cannell P, Irving I, JF Seymour.
Contemporary Clinical Trials Communications 4: 9-13.
Memberships
Donations
Clinical Trials & Research